Online inquiry

X-Ray Diffraction

Creative Biolabs has been focused on mRNA research for many years and has accumulated a wealth of project experience. With the advanced equipment and expertise, we can provide a wide range of customized solutions for mRNA delivery based on X-ray diffraction. Following are some examples of this technology in use.

Characteristics of Solid Lipid Nanoparticles (SLNs) by X-Ray Diffraction

SLNs were prepared by improved high shear homogenization and ultrasonic technology. The model drug mifepristone has been added. The average particle size measured by laser diffraction (LD) was 106 nm and the polydispersity index was 0.278. The X-ray diffraction data shown in Fig.1 is in good agreement with the DSC measurement results. Compared with the nanoparticles with relatively sharp peaks, the diffraction spectra of the bulk matrix are significantly different. Obviously, in both drug-free and drug-loading SLNS, crystals with a lower degree of the order are dominant, and amorphous states contribute to higher drug-loading capacity. It is also clear from the X-ray diagram that the crystal state of the model drug mifepristone in SLN does not exist at all due to the disappearance of the sharp peak of the pure substance. DSC and X-ray diffraction showed that the crystal arrangement of most SLNS was not so orderly, which was conducive to improving drug loading capacity.

X-ray diffraction pattern. 1#-Pure mifepristone, 2#-bulk material, 3#-Placebo SLNs, 4#-lyophilization SLNs powder containing 2 mg/ml model drug.Fig.1 X-ray diffraction pattern. 1#-Pure mifepristone, 2#-bulk material, 3#-Placebo SLNs, 4#-lyophilization SLNs powder containing 2 mg/ml model drug. (Hou, 2003)

Preparation and Stabilization of Nifedipine Lipid Nanoparticles

Scientists studied the preparation of nifedipine (NI) nanoparticles without using any organic solvent. NI nanoparticles with an average particle size of about 50nm could be prepared by a combination of roll mixing and high-pressure homogenization without organic solvent. The powder X-ray diffraction pattern of the NI-lipid mixture prepared by the roll milling method is shown in Fig.2. In the patterns of NI alone, the physical mixture of NI and lipid, and NI-lipid roll mill mixture, NI-specific diffraction peaks appeared at 8.2, 16.2, 19.6, 24.4, and 25.9°. As for the sample co-ground by roll milling, the peaks were reduced, but the pattern was similar to that of the physical mixture. Researchers reported that the crystal form of poorly soluble drugs disappeared after co-grinding with a carrier, and the formation of the amorphous state allowed the preparation of solid dispersion. In this study, the X-ray diffraction peak of the sample after mixing was present at the position of NI crystals, and no peak shift was induced by interaction with lipid, showing that NI mostly remained as crystals in the lipid.

Powder X-ray diffraction patterns of main components NI-lipid prepared by roll milling. NI-lipid mixture: NI and lipid were ground by roll milling for 5min.Fig.2 Powder X-ray diffraction patterns of main components NI-lipid prepared by roll milling. NI-lipid mixture: NI and lipid were ground by roll milling for 5min. (Kamiya, 2008)

Creative Biolabs is a world-leading biotechnology company. We offer well-established and innovative one-stop-shop mRNA delivery solutions. Our strategic consultants and technical team are the most renowned experts in their fields. We are flexible to meet the unique needs of mRNA client projects. You can count on our skilled and passionate workforce to find the most suitable solution. Please contact us for more information and a detailed quote.

References

  1. Hou, D.Z.; et al. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials. 2003, 24(10): 1781-1785.
  2. Kamiya, S.; et al. Preparation and stabilization of nifedipine lipid nanoparticles. International journal of pharmaceutics. 2008, 354(1-2): 242-247.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.